AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

被引：42
|
作者：
Fong, P. C.
Boss, D. S.
Carden, C. P.
Roelvink, M.
De Greve, J.
Gourley, C. M.
Carmichael, J.
De Bono, J. S.
Schellens, J. H.
Kaye, S. B.
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] UZ Brussel, Ctr Oncol, Brussels, Belgium
[4] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[5] Kudos Pharmaceut, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5510
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5510
引用
收藏
页数：1
相关论文
共 50 条
  • [41] First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers
    Wenham, R.
    Wilding, G.
    Baird, R.
    Sun, L.
    Toniatti, C.
    Stroh, M.
    Carpenter, C.
    de-Bono, J.
    Sandhu, S.
    Schelman, W.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S5 - S6
  • [42] Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and platinum sensitive recurrent ovarian cancer
    Li, N.
    Wu, L.
    Zhang, Y.
    Liu, J.
    Zhou, Q.
    Zhu, J.
    Yin, R.
    Wang, L.
    Li, G.
    Wu, X.
    Pan, H.
    Yao, S.
    Wu, Q.
    Gu, K.
    Zhang, H.
    Wan, X.
    An, R.
    Zou, J.
    Wang, Q.
    ANNALS OF ONCOLOGY, 2019, 30 : 408 - 408
  • [43] Phase I Study of the Poly (ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
    Plummer, Ruth
    Jones, Christopher
    Middleton, Mark
    Wilson, Richard
    Evans, Jeffrey
    Olsen, Anna
    Curtin, Nicola
    Boddy, Alan
    McHugh, Peter
    Newell, David
    Harris, Adrian
    Johnson, Patrick
    Steinfeldt, Heidi
    Dewji, Raz
    Wang, Diane
    Robson, Lesley
    Calvert, Hilary
    CLINICAL CANCER RESEARCH, 2008, 14 (23) : 7917 - 7923
  • [44] Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC).
    Ang, J.
    Yap, T. A.
    Fong, P.
    Carden, C. P.
    Tan, D. S.
    Hanwell, J.
    Carmichael, J.
    De Bono, J. S.
    Gore, M. E.
    Kaye, S. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort
    Konstantinopoulos, Panagiotis A.
    Barry, William T.
    Birrer, Michael
    Westin, Shannon N.
    Farooq, Sarah
    Cadoo, Karen
    Whalen, Christin
    Luo, Weixiu
    Liu, Hui
    Aghajanian, Carol
    Solit, David B.
    Mills, Gordon B.
    Taylor, Barry S.
    Won, Helen
    Berger, Michael F.
    Palakurthi, Sangeetha
    Liu, Joyce F.
    Cantley, Lew
    Kaufmann, Scott H.
    Swisher, Elizabeth M.
    D'Andrea, Alan D.
    Winer, Eric
    Wulf, Gerburg M.
    Matulonis, Ursula A.
    CANCER RESEARCH, 2017, 77
  • [46] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
    LoRusso, Patricia M.
    Li, Jing
    Burger, Angelika
    Heilbrun, Lance K.
    Sausville, Edward A.
    Boerner, Scott A.
    Smith, Daryn
    Pilat, Mary Jo
    Zhang, Jie
    Tolaney, Sara M.
    Cleary, James M.
    Chen, Alice P.
    Rubinstein, Lawrence
    Boerner, Julie L.
    Bowditch, Adam
    Cai, Dongpo
    Bell, Tracy
    Wolanski, Andrew
    Marrero, Allison M.
    Zhang, Yiping
    Ji, Jiuping
    Ferry-Galow, Katherine
    Kinders, Robert J.
    Parchment, Ralph E.
    Shapiro, Geoffrey I.
    CLINICAL CANCER RESEARCH, 2016, 22 (13) : 3227 - 3237
  • [47] First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors
    Kopetz, S.
    Mita, M. M.
    Mok, I.
    Sankhala, K. K.
    Moseley, J.
    Sherman, B. M.
    Bradley, C. R.
    Tolcher, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] PHASE I STUDY OF A POLY(ADP)-RIBOSE POLYMERASE (PARP) INHIBITOR MK-4827 (MK) WITH ANTITUMOUR ACTIVITY IN SPORADIC CASTRATION RESISTANT PROSTATE CANCER (CRPC)
    Sandhu, S. K.
    Moreno, V.
    Wilding, G.
    Omlin, A.
    Schelman, W. R.
    Miranda, S.
    Riinaes, R.
    Hylands, L.
    Attard, G.
    Cassidy, A.
    Kreischer, N.
    Carpenter, C.
    Demuth, T.
    Wenham, R. M.
    de-Bono, J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 33 - 33
  • [49] Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety
    Kristeleit, Rebecca S.
    Oaknin, Ana
    Ray-Coquard, Isabelle
    Leary, Alexandra
    Balmana, Judith
    Drew, Yvette
    Oza, Amit M.
    Shapira-Frommer, Ronnie
    Domchek, Susan M.
    Cameron, Terri
    Maloney, Lara
    Goble, Sandra
    Lorusso, Domenica
    Ledermann, Jonathan A.
    McNeish, Iain A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (09) : 1396 - 1404
  • [50] Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors.
    Tan, A. R.
    Toppmeyer, D.
    Stein, M. N.
    Moss, R. A.
    Gounder, M.
    Lindquist, D. C.
    Ji, J. J.
    Chen, A. P.
    Egorin, M. J.
    Kiesel, B.
    Beumer, J. H.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345